Former GoodRx Interim CEO brings a deep understanding of the GoodRx business and extensive leadership experience to his role as Co-Chair of the Board

GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced that Scott Wagner has joined its Board of Directors, effective January 21, 2025. Mr. Wagner, who recently led GoodRx as its Interim Chief Executive Officer from April 2023 to January 2025, has been appointed as Co-Chair of the Board and will serve alongside existing Co-Chair Trevor Bezdek.

Wagner joins the Board with more than 25 years of executive leadership experience, including his impactful tenure as Chief Executive Officer and President/Chief Operating Officer/Chief Financial Officer at GoDaddy. During his time at the company, GoDaddy expanded its services globally and saw an exceptional tripling in revenue, reaching nearly $3 billion, establishing it as a powerhouse in internet domain and web services. Prior to GoDaddy, Mr. Wagner served as a Partner at KKR, a global investment company, where he worked from 2000 to 2012 as one of the leads of KKR’s Capstone team.

“We are excited to welcome Scott into his new position on the board where he will continue to play an important role in driving forward the strategic vision he helped lay out for the company over the last year and a half,” said Trevor Bezdek, co-founder and Co-Chair of the Board of GoodRx. “Scott’s deep understanding of our business will further empower GoodRx as we embark on our next stage of growth and innovation.”

Mr. Wagner will also serve as the chairperson of the Board’s Compensation Committee. The board appointment coincides with the resignation of Simon Patterson, who stepped down as a director and member of the Board’s Nominating and Corporate Governance Committee and Innovation Committee, effective January 21, 2025.

About GoodRx

GoodRx is the leading prescription savings platform in the U.S. Trusted by nearly 30 million consumers and over one million healthcare professionals annually, GoodRx provides access to savings and affordability options for generic and brand-name medications at more than 70,000 pharmacies nationwide, as well as comprehensive healthcare research and information. Since 2011, GoodRx has helped consumers save over $75 billion on the cost of their prescriptions.

GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, the statements regarding anticipated contributions from Scott Wagner in his directorship and expected benefits to the Company and our Board. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Press Contact GoodRx press@goodrx.com

GoodRx (NASDAQ:GDRX)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more GoodRx Charts.
GoodRx (NASDAQ:GDRX)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more GoodRx Charts.